Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive and Nonradioactive

Impact of residual [18F]Fluoride in diagnosis of neuroblastoma patients from [18F]FDOPA routine production

Ya-Yao Huang, Kai-Yuan Tzen, Ching-Hong Chiu, Chia-Ling Tsai, Hsiang-Ping Wen, Kuang-Hua Tang and Chyng-Yann Shiue
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 164;
Ya-Yao Huang
1Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai-Yuan Tzen
1Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ching-Hong Chiu
1Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia-Ling Tsai
1Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hsiang-Ping Wen
1Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuang-Hua Tang
1Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chyng-Yann Shiue
1Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

164

Objectives [18F]FDOPA(FDOPA) has been used in the diagnosis of Neuroblastoma (NB) by targeting the overexpression of amino acid decarboxylase in NB cells. A great portion of NB patients may have skeletal metastases. Detection of [18F]F- is not included in the USP monograph specification of FDOPA. The residual [18F]F- content in FDOPA production may result in bony uptake instead of tumor uptake. The aim of our study is to assess the impact of residual [18F]F- in NB diagnosis and to implement a method to maintain low [18F]F- content.

Methods Automatic synthesis of FDOPA was based on the electrophilic method using TRACERlab FXFE module. Radio-TLC method was employed with RP-18 TLC plate for determination of the residual [18F]F- level. We recruited 60 patients (age 0.1-18 years) with NB to receive FDOPA PET at initial diagnosis and follow-ups. The residual [18F]F- levels in each FDOPA batch were correlated with the skeleton uptakes in PET images.

Results From Sep. 2010 to Mar. 2012, the residual [18F]F- levels were in the range of 0.2%-19.1% in 82 batches of production. 181 FDOPA PET scans were performed. Comparing the PET images of same patients in different studies, we found that the residual [18F]F- levels (>4.0%) would show significant growth plate uptake and may disturb the interpretation. 80% of FDOPA productions showed that the [18F]F- levels were >4.0 %. To achieve a low level of residual [18F]F-, we replaced the HPLC column and chemical reagents (NH4(aq)) every 30 runs or when [18F]F- level >3.0%. Up to Dec. 2012, the level of residual [18F]F- were kept <4.0% in all FDOPA batches (n=60).

Conclusions By monitoring the residual [18F]F- level in final [18F]FDOPA product and keeping the stringent procedures, we can keep the [18F]F- content to be lower than 4% in all [18F]FDOPA productions. We expect that there will be no more significant bony uptake in future studies. Furthermore, the appropriate level of [18F]F- (<4.0%) maybe needed to be included in the criteria of routine quality control of [18F]FDOPA.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 54, Issue supplement 2
May 2013
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of residual [18F]Fluoride in diagnosis of neuroblastoma patients from [18F]FDOPA routine production
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Impact of residual [18F]Fluoride in diagnosis of neuroblastoma patients from [18F]FDOPA routine production
Ya-Yao Huang, Kai-Yuan Tzen, Ching-Hong Chiu, Chia-Ling Tsai, Hsiang-Ping Wen, Kuang-Hua Tang, Chyng-Yann Shiue
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 164;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of residual [18F]Fluoride in diagnosis of neuroblastoma patients from [18F]FDOPA routine production
Ya-Yao Huang, Kai-Yuan Tzen, Ching-Hong Chiu, Chia-Ling Tsai, Hsiang-Ping Wen, Kuang-Hua Tang, Chyng-Yann Shiue
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 164;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive and Nonradioactive

  • PET imaging and biodistribution analysis of an acetylated [68Ga]GLP-1 analogue in a xenograft insulinoma mouse model
  • Synthesis and validation of cFLFLF-PEG76-99mTc, a neutrophil-targeting gamma imaging probe, with a bacteria-infected rabbit model
  • Long lived radionuclidic impurities in FASTlab F-18 FDG citrate
Show more Molecular Targeting Probes - Radioactive and Nonradioactive

Radiopharmacy

  • Radiochemical Purity of Common On-Call Kits Utilizing Tc-99m Eluate Near Its Beyond Use Date
  • The Inconsistencies of Iodine Capsule Dosimetry and Calibration
  • Comparison Between the NorthStar RadioGenix® System and Traditional Dry-Column Generators for the Production of Technetium-99m
Show more Radiopharmacy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire